Progenity Inc. (PROG): Price and Financial Metrics

Progenity Inc. (PROG): $0.88

0.03 (-3.47%)

POWR Rating

Component Grades








Add PROG to Watchlist
Sign Up

Industry: Biotech




#341 of 394

in industry

PROG Price/Volume Stats

Current price $0.88 52-week high $6.20
Prev. close $0.92 52-week low $0.66
Day low $0.84 Volume 2,779,600
Day high $0.92 Avg. volume 8,589,605
50-day MA $1.17 Dividend yield N/A
200-day MA $1.85 Market Cap 162.92M

PROG Stock Price Chart Interactive Chart >

Progenity Inc. (PROG) Company Bio

Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

PROG Latest News Stream

Event/Time News Detail
Loading, please wait...

PROG Latest Social Stream

Loading social stream, please wait...

View Full PROG Social Stream

Latest PROG News From Around the Web

Below are the latest news stories about Progenity Inc that investors may wish to consider to help them evaluate PROG as an investment opportunity.

Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22

Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitisSAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared two poster presentations that were presented during the 17th Congre

Yahoo | February 22, 2022

Progenity (PROG) Receives a Buy from H.C. Wainwright


Catie Powers on TipRanks | February 16, 2022

Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomesSAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today shared an oral presentation that was delivered by Dr. Bram Verstockt during the 34th edition of the Belgian Week of Gastroenterology on February 9, 2022. During the oral presentation t

Yahoo | February 16, 2022

10 Stocks to Buy That Could Make You a Millionaire in 2022

After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022.

Will Ashworth on InvestorPlace | January 26, 2022

Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support. “We have added another important patent t

Yahoo | January 25, 2022

Read More 'PROG' Stories Here

PROG Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -75.21%
5-year N/A
2023 N/A
2022 0.00%
2021 -60.64%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!